For adults with type 2 diabetes uncontrolled on one or more oral antidiabetic agents along
with diet and exercise to improve glycemic control

Device designed to be patient-friendly to help get consistent control with once-weekly exenatide1

X


WATCH THIS VIDEO IN SPANISH
MIRA ESTE VIDEO EN ESPAÑOL

Remember to read the full Instructions for Use and Prescribing Information for BYDUREON BCise for complete instructions.

  • Only pressure-activated device with no button required for type 2 diabetes1
  • No titration, no doses to dial1
  • Pre-attached hidden needle1

The easy-to-use* device with once-weekly BYDUREON BCise2

*In a human factor validation study, most participants, 89 of 104 (85.5%), rated the complete overall injection task as either easy or very easy.2

Once-weekly exenatide in 3 simple steps1

Click on the images below for each step.

3 simple steps to BCise dosing: Mix the medicine inside BCise, unlock BCise, and inject BCise
3 simple steps to BCise dosing: Mix the medicine inside BCise, unlock BCise, and inject BCise
3 simple steps to BCise dosing: Mix the medicine inside BCise, unlock BCise, and inject BCise

  • Remove the device from the refrigerator, rest it flat for at least 15 minutes to allow it come to room temperature and prepare injection site

  • Do not unlock before mixing

  • Holding the device with the orange cap pointing towards the ceiling, shake the autoinjector hard for at least 15 seconds until the medicine is mixed evenly

  • Do not unlock before suspension is mixed well

  • With the orange cap pointing towards the ceiling, firmly unscrew the orange cap counterclockwise to unlock the device

  • Inject subcutaneously in the abdomen, thigh, or back of upper arm by pushing the autoinjector against the skin and holding it there for 15 seconds to get the full dose

Remember to read the full Instructions for Use and Prescribing Information for BYDUREON BCise for complete instructions.

Storage flexibility

Storage flexibility1

  • Store flat in the refrigerator at 36°F to 46°F (2°C to 8°C), or

  • Store flat at room temperature (up to 86°F) for up to 4 weeks

  • Do not freeze or use BYDUREON BCise if it has been frozen

  • Protect BYDUREON BCise from light

SAVINGS CARD
DISCOVER ONCE-WEEKLY BYDUREON BCise
SEE THE SAFETY PROFILE OF BYDUREON BCise
EXPERIENCE WHAT'S INSIDE BYDUREON BCise

X


IMPORTANT SAFETY INFORMATION

open isi

WARNING: RISK OF THYROID C-CELL TUMORS

  • Exenatide extended-release causes an increased incidence in thyroid C-cell tumors at clinically relevant exposures in rats compared to controls. It is unknown whether BYDUREON or BYDUREON BCise cause thyroid C-cell tumors, including medullary thyroid carcinoma (MTC) in humans, as the human relevance of exenatide extended-release-induced rodent thyroid C-cell tumors has not been determined

  • BYDUREON and BYDUREON BCise are contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Counsel patients regarding the potential risk of MTC with the use of BYDUREON or BYDUREON BCise and inform them of symptoms of thyroid tumors (eg, mass in the neck, dysphagia, dyspnea, persistent hoarseness). Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for detection of MTC in patients treated with BYDUREON or BYDUREON BCise

CONTRAINDICATIONS

  • For BYDUREON and BYDUREON BCise: Personal or family history of MTC, patients with MEN 2

  • Prior serious hypersensitivity reactions to exenatide or product components

WARNINGS AND PRECAUTIONS

  • Acute Pancreatitis including fatal and non-fatal hemorrhagic or necrotizing pancreatitis has been reported. After initiation, observe patients carefully for symptoms of pancreatitis. If suspected, discontinue promptly and do not restart if confirmed. Consider other antidiabetic therapies in patients with a history of pancreatitis

  • Never Share Injection Device or Needle Between Patients Sharing poses a risk for transmission of blood-borne pathogens, even if the needle is changed

  • Hypoglycemia Risk of hypoglycemia is increased when exenatide is coadministered with insulin or insulin secretagogues. Consider lowering the dose of these agents when coadministered with BYDUREON, BYDUREON BCise or BYETTA

  • Acute Kidney Injury and Impairment of Renal Function May induce nausea and vomiting with transient hypovolemia and may worsen renal function. Altered renal function, including increased serum creatinine, renal impairment, worsened chronic renal failure, and acute renal failure, sometimes requiring hemodialysis and kidney transplantation have been reported. BYDUREON or BYDUREON BCise are not recommended in patients with eGFR <45 mL/min/1.73 m2. BYETTA should not be used in patients with severe renal impairment or end-stage renal disease and should be used with caution in patients with moderate renal impairment or renal transplantation

  • Gastrointestinal Disease Because exenatide is commonly associated with gastrointestinal adverse reactions, not recommended in patients with severe gastrointestinal disease (eg, gastroparesis)

  • Immunogenicity Patients may develop antibodies to exenatide. Patients with higher titer antibodies may have an attenuated HbA1c response. In clinical trials, attenuated glycemic response was associated with BYDUREON-, BYDUREON BCise-, or BYETTA-treated patients. If worsening of or failure to achieve adequate glycemic control occurs, consider alternative antidiabetic therapy

  • Hypersensitivity Reports of serious hypersensitivity reactions (eg, anaphylaxis and angioedema). If this occurs, patients should discontinue BYDUREON, BYDUREON BCise or BYETTA and promptly seek medical advice

  • Injection-Site Reactions Serious reactions (eg, abscess, cellulitis, and necrosis), with or without subcutaneous nodules, have been reported with extended-release exenatide

  • Acute Gallbladder Disease has been reported in GLP-1 receptor agonist trials, including exenatide. If cholelithiasis or cholecystitis are suspected, gallbladder studies are indicated

  • Macrovascular Outcomes No clinical studies establishing conclusive evidence of macrovascular risk reduction with BYETTA

ADVERSE REACTIONS

  • Most common (≥5%) and occurring more frequently than comparator in BYDUREON clinical trials: nausea (16.9%), diarrhea (12.7%), headache (8.0%), vomiting (6.8%), constipation (5.9%), injection-site pruritus (5.9%), injection-site nodule (5.3%), dyspepsia (5.1%)

  • Most common (≥5%) in BYDUREON BCise clinical trials: injection-site nodule (10.5%), nausea (8.2%)

  • Most common (≥5%) and occurring more frequently than placebo in BYETTA clinical trials: nausea (8%-44%), hypoglycemia (3.8%-35.7%), vomiting (4%-18%), diarrhea (6%-18%), feeling jittery (9%), dizziness (9%), headache (9%-14%), dyspepsia (3%-7%), constipation (10%), asthenia (4%-5%)

DRUG INTERACTIONS

  • Oral Medications BYDUREON, BYDUREON BCise and BYETTA slow gastric emptying and may reduce the rate of absorption of orally administered drugs

  • Warfarin Increased international normalized ratio (INR) sometimes associated with bleeding has been reported with concomitant use of exenatide with warfarin. Monitor INR frequently until stable upon initiation of BYDUREON, BYDUREON BCise, or BYETTA

PREGNANCY

Use during pregnancy only if the potential benefit justifies the potential risk to the fetus.

INDICATION AND LIMITATIONS OF USE

BYDUREON, BYDUREON BCise and BYETTA are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus

  • BYDUREON or BYDUREON BCise is not recommended as first-line therapy for patients inadequately controlled on diet and exercise

  • BYDUREON, BYDUREON BCise or BYETTA is not a substitute for insulin. Should not be used to treat type 1 diabetes or diabetic ketoacidosis

  • BYDUREON and BYETTA have not been studied with prandial insulin. BYDUREON BCise is not recommended for use with insulin

  • Do not coadminister with other exenatide-containing products

  • Not studied in patients with a history of pancreatitis. Consider other antidiabetic therapies in patients with a history of pancreatitis

You may report side effects related to AstraZeneca products by clicking here.

Abbreviation: GLP-1 RA, glucagon-like peptide-1 receptor agonist.

References:

  1. BYDUREON BCise® ([exenatide extended-release] injectable suspension) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2019.

  2. Data on file, REF-14053. AstraZeneca Pharmaceuticals LP.

Abbreviations: FDA, US Food and Drug Administration; GLP-1 RA, glucagon-like peptide-1 receptor agonist.

References:

  1. BYETTA® ([exenatide] injection) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2018.

  2. BYDUREON® ([exenatide extended-release] injectable suspension) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2019.

  3. BYDUREON BCise® ([exenatide extended-release] injectable suspension) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2019.

  4. Data on file, REF-14053. AstraZeneca Pharmaceuticals LP.

  5. Data on file, REF-33646. AstraZeneca Pharmaceuticals LP.

  6. Data on file, US-20428. AstraZeneca Pharmaceuticals LP.

Abbreviation: GLP-1 RA, glucagon-like peptide-1 receptor agonist.

References:

  1. Bunck MC, Diamant M, Cornér A, et al. One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial. Diabetes Care. 2009;32(5):762-768.

  2. Bunck MC, Corner A, Eliasson B, et al. Effects of exenatide on measures of beta-cell function after 3 years in metformin-treated patients with type 2 diabetes. Diabetes Care. 2011;34(9):2041-2047.

  3. DeFronzo RA. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes. 2009;58(4):773-795.

  4. BYDUREON® ([exenatide extended-release] injectable suspension) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2019.

  5. BYETTA® ([exenatide] injection) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2018.

  6. Van Bloemendaal L, IJzerman RG, Ten Kulve JS, et al. GLP-1 receptor activation modulates appetite- and reward-related brain areas in humans. Diabetes. 2014;63(12):4186-4196.

  7. Larsson H, Holst JJ, Ahrén B. Glucagon-like peptide-1 reduces hepatic glucose production indirectly through insulin and glucagon in humans. Acta Physiol Scand. 1997;160(4):413-422.

  8. Campbell JE, Drucker DJ. Pharmacology, physiology, and mechanisms of incretin hormone action. Cell Metab. 2013;17(6):819-837.

  9. DeFronzo RA, Eldor R, Abdul-Ghani M. Pathophysiologic approach to therapy in patients with newly diagnosed type 2 diabetes. Diabetes Care. 2013;36(suppl 2):S127-S138.

  10. Garber AJ, Abrahamson MJ, Barzilay JI, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm – 2018 executive summary. Endocr Pract. 2018;24(1):91-120.

  11. Aronoff SL, Berkowitz K, Shreiner B, Want L. Glucose metabolism and regulation: beyond insulin and glucagon. Diabetes Spectrum. 2004;17(3):183-190.

  12. Prasad-Reddy L, Isaacs D. A clinical review of GLP-1 receptor agonists: efficacy and safety in diabetes and beyond. Drugs Context. 2015;4:212283. doi:10.7573/dic.212283. Accessed April 19, 2018.

Abbreviations: BL, baseline; GLP-1 RA, glucagon-like peptide-1 receptor agonist; PK, pharmacokinetic.

References:

  1. BYDUREON BCise® ([exenatide extended-release] injectable suspension) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2019.

  2. Data on file, REF-14053. AstraZeneca Pharmaceuticals LP.

Abbreviations: BID, twice daily; BL, baseline; GLP-1 RA, glucagon-like peptide-1 receptor agonist; ITT, intent-to-treat; QW, once weekly; SU, sulfonylurea; TZD, thiazolidinedione.

References:

  1. DeYoung MB, MacConell L, Sarin V, Trautmann M, Herbert P. Encapsulation of exenatide in poly-(D,L-lactide-co-glycolide) microspheres produced an investigational long-acting once-weekly formulation for type 2 diabetes. Diabetes Technol Ther. 2011;13(11):1145-1154.

  2. Data on file, REF-19541. AstraZeneca Pharmaceuticals LP.

Abbreviations: FPG, fasting plasma glucose; GLP-1 RA, glucagon-like peptide-1 receptor agonist; PK, pharmacokinetic; SE, standard error.

References:

  1. BYDUREON BCise® ([exenatide extended-release] injectable suspension) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2019.

  2. Data on file, REF-19541. AstraZeneca Pharmaceuticals LP.

  3. Data on File, REF-33652. AstraZeneca Pharmaceuticals LP.

  4. Wysham CH, Rosenstock J, Vetter M, Dong F, Öhman P, Iqbal N. Efficacy and tolerability of the new autoinjected suspension of exenatide once weekly versus exenatide twice daily in patients with type 2 diabetes. Diabetes Obes Metab. 2018;20(1):165-172.

Abbreviations: BID, twice daily; BL, baseline; ITT, intent-to-treat; QD, once daily; QW, once weekly; SU, sulfonylurea; TZD, thiazolidinedione.

References:

  1. BYDUREON BCise® ([exenatide extended-release] injectable suspension) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2019.

  2. Data on file, REF-22126. AstraZeneca Pharmaceuticals LP.

  3. Diamant M, Van Gaal L, Stranks S, et al. Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial. Lancet. 2010;375(9733):2234-2243.

  4. Bergenstal RM, Wysham C, MacConell L, et al; for the DURATION-2 Study Group. Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial. Lancet. 2010;376(9739):431-439.

  5. Russell-Jones D, Cuddihy RM, Hanefeld M, et al; on behalf of the DURATION-4 Study Group. Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study. Diabetes Care. 2012;35(2):252-258.

  6. Blevins T, Pullman J, Malloy J, et al. DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes. J Clin Endocrinol Metab. 2011;96(5):1301-1310.

  7. Gadde KM, Vetter ML, Iqbal N, et al. DURATION-NEO-2 study investigators. Efficacy and safety of autoinjected exenatide once-weekly suspension versus sitagliptin or placebo with metformin in patients with type 2 diabetes: the DURATION-NEO-2 randomized clinical study. Diabetes Obes Metab. 2017;19(7):979-988.

  8. Wysham CH, Rosenstock J, Vetter M, Dong F, Öhman P, Iqbal N. Efficacy and tolerability of the new autoinjected suspension of exenatide once weekly versus exenatide twice daily in patients with type 2 diabetes. Diabetes Obes Metab. 2018;20(1):165-172.

Abbreviations: AE, adverse event; BID, twice daily; ITT, intent-to-treat; QW, once weekly; SU, sulfonylurea; TZD, thiazolidinedione.

References:

  1. Data on file, US-20428. AstraZeneca Pharmaceuticals LP.

  2. BYDUREON BCise® ([exenatide extended-release] injectable suspension) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2019.

  3. DeYoung MB, MacConell L, Sarin V, Trautmann M, Herbert P. Encapsulation of exenatide in poly-(D,L-lactide-co-glycolide) microspheres produced an investigational long-acting once-weekly formulation for type 2 diabetes. Diabetes Technol Ther. 2011;13(11):1145-1154.

  4. BYDUREON® ([exenatide extended-release] injectable suspension) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2019.

  5. Data on file, REF-5087. AstraZeneca Pharmaceuticals LP.

  6. Wysham CH, Rosenstock J, Vetter M, Dong F, Öhman P, Iqbal N. Efficacy and tolerability of the new autoinjected suspension of exenatide once weekly versus exenatide twice daily in patients with type 2 diabetes. Diabetes Obes Metab. 2018;20(1):165-172.

References:

  1. BYDUREON BCise® ([exenatide extended-release] injectable suspension) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2019.

  2. Data on file, REF-14053. AstraZeneca Pharmaceuticals LP.

Abbreviations: CGM, continuous glucose monitoring; FPG, fasting plasma glucose; MET, metformin; mITT, modified intent-to-treat; MXR, metformin extended-release; PPG, postprandial glucose.

References:

  1. Data on file, REF-5039. AstraZeneca Pharmaceuticals LP.

  2. Frias JP, Nakhle S, Ruggles JA, et al. Exenatide once weekly improved 24-hour glucose control and reduced glycaemic variability in metformin-treated participants with type 2 diabetes: a randomized, placebo-controlled trial [published online ahead of print August 16, 2016]. Diabetes Obes Metab. doi:10.1111/dom.12763.

Abbreviations: BL, baseline; IG, insulin glargine; LS, least squares; MET, metformin; SU, sulfonylurea; TZD, thiazolidinediones.

References:

  1. BYDUREON® ([exenatide extended-release] injectable suspension) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2019.

  2. Diamant M, Van Gaal L, Stranks S, et al. Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial. Lancet. 2010;375(9733):2234-2243.

  3. Frías JP, Guja C, Hardy E, et al. Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial. Lancet Diabetes Endocrinol. 2016;4(12):1004-1016.

Abbreviations: BID, twice daily; IU, international unit; QW, once weekly.

References:

  1. BYDUREON® ([exenatide extended-release] injectable suspension) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2019.

  2. Data on file, REF-7842. AstraZeneca Pharmaceuticals LP.

  3. Drucker DJ, Buse JB, Taylor K, et al. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet. 2008;372(9645):1240-1250.

  4. Wysham CH, Philis-Tsimikas A, Klein EJ, et al. DURATION-1 extension in patients with type 2 diabetes: efficacy and tolerability of exenatide once weekly over 7 years [poster]. Presented at: 76th Annual Scientific Sessions of American Diabetes Association; June 10-14, 2016; New Orleans, LA. Poster 1041-P.

  5. Diamant M, Van Gaal L, Guerci B, et al. Exenatide once weekly versus insulin glargine for type 2 diabetes (DURATION-3): 3-year results of an open-label randomised trial. Lancet Diabetes Endocrinol. 2014;2(6):464-473.

  6. Data on file, REF-5090. AstraZeneca Pharmaceuticals LP.

  7. Data on file, REF-4977. AstraZeneca Pharmaceuticals LP.

Abbreviations: PK, pharmacokinetics.

Reference:

  1. BYDUREON® ([exenatide extended-release] injectable suspension) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2019.

Abbreviation: GF, glucose fluctuation.